CureVac Lipid C24(CVL1,VitE-C4DE-Pip- S)
Version 1.087b0bba · 2026-09-13
| CAS No. | Not available |
| Chemical Name | CureVac Lipid C24(CVL1,VitE-C4DE-Pip- S) |
| Synonyms | CureVac Lipid-C24 |
| SMILES | C1C(CCOC(=O)CCC(=O)OC2=C(C)C(C)=C3O[C@H0](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CCC3=C2C)CCN(CCSCCN2CCC(CCOC(=O)CCC(=O)OC3=C(C)C4CC[C@@H0](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)OC=4C(C)=C3C)CC2)C1.Cl.Cl |
| Formula | C84H142O10Cl2N2S |
| M.Wt | 1,443.02 |
| Purity | >98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Not available |
CVL1 (C24), also known as VitE-C4DE-Pip-S, is a vitamin E-derived ionizable lipid developed for lipid nanoparticle-mediated delivery of mRNA and other nucleic acids developed by CureVac. It features two hydrophobic α-tocopherol moieties connected to a bis-piperidine ionizable core through biodegradable succinate ester linkages, while a central thioether-containing spacer provides additional structural flexibility. CVL1 can be incorporated into LNP formulations to support nucleic acid encapsulation, cellular uptake, and intracellular delivery. CureVac has investigated CVL1-containing LNPs for mRNA expression in immune-related tissues and cells, including the spleen, lymph nodes, and antigen-presenting cells, making it a valuable research lipid for mRNA vaccines, cancer immunotherapy, and other nucleic acid delivery applications.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →